Cabozantinib

What is Cabozantinib?

Cabozantinib is an advanced pharmaceutical compound classified as a multi-targeted receptor tyrosine kinase inhibitor (TKI). It is used primarily in the treatment of various advanced and metastatic cancers. Marketed under brand names such as Cometriq® and Cabometyx®, it represents a significant advancement in targeted cancer therapies. Unlike traditional chemotherapy, which often targets rapidly dividing cells indiscriminately, Cabozantinib works by specifically inhibiting multiple protein kinases that are crucial for cancer cell growth, survival, and metastasis. This targeted approach aims to minimize damage to healthy cells while effectively combating the disease, offering a more precise and often better-tolerated treatment option for eligible patients.

How Does it Work?

The mechanism of action of Cabozantinib is complex and multi-faceted, targeting several key pathways involved in tumor progression. It inhibits the activity of multiple receptor tyrosine kinases (RTKs) that are known to be aberrantly activated in many human cancers. Key targets include:

• MET (Mesenchymal-Epithelial Transition factor): A receptor involved in cell proliferation, survival, and motility.
• VEGFR1, VEGFR2, and VEGFR3 (Vascular Endothelial Growth Factor Receptors): These receptors play a critical role in angiogenesis, the formation of new blood vessels that tumors need to grow and spread.
• AXL: Involved in cell proliferation, survival, and drug resistance.
• RET (Rearranged during Transfection): A proto-oncogene often mutated in certain thyroid cancers.
• KIT: A receptor tyrosine kinase involved in cell growth and survival.

By inhibiting these specific kinases, Cabozantinib effectively disrupts several processes vital for tumor development: it reduces tumor angiogenesis (starving the tumor of blood supply), inhibits tumor cell proliferation, and decreases metastasis. This comprehensive attack on multiple cancer-driving pathways makes Cabozantinib a powerful tool against challenging malignancies.

Medical Uses

Cabozantinib has received regulatory approval for the treatment of several advanced and metastatic cancers, demonstrating significant clinical benefit in these settings:

• Advanced Renal Cell Carcinoma (RCC)

  Cabozantinib is approved for patients with advanced renal cell carcinoma (RCC) who have received prior anti-angiogenic therapy. It has shown superiority over other treatments in improving progression-free survival and overall survival in this population, making it a crucial second-line or later-line option.

• Progressive, Metastatic Medullary Thyroid Cancer (MTC)

  For patients with progressive, metastatic medullary thyroid cancer (MTC), Cabozantinib (under the brand name Cometriq®) is indicated. MTC is a rare form of thyroid cancer, and Cabozantinib's ability to inhibit the RET kinase is particularly relevant here, as RET mutations are common drivers of MTC.

• Hepatocellular Carcinoma (HCC)

  Cabozantinib is also approved for patients with hepatocellular carcinoma (HCC) who have been previously treated with sorafenib. HCC, a common type of liver cancer, is aggressive, and Cabozantinib provides an important second-line treatment option, demonstrating improved overall survival compared to placebo.

Its use is typically reserved for patients whose disease has progressed despite initial therapies, highlighting its role in extending life and controlling disease in difficult-to-treat cancers.

Dosage

The dosage of Cabozantinib varies depending on the specific cancer being treated and the patient's individual response and tolerability. It is administered orally, typically once daily, with or without food. It is crucial to follow the prescribing physician's instructions precisely, as dose adjustments may be necessary based on side effects or therapeutic response.

• For Renal Cell Carcinoma and Hepatocellular Carcinoma: The usual recommended starting dose is 60 mg orally once daily.
• For Medullary Thyroid Cancer: The usual recommended starting dose is 140 mg (two 80 mg capsules or equivalent) orally once daily.

Cabozantinib is available in different tablet strengths (e.g., 20 mg, 40 mg, 60 mg) or capsule strengths (e.g., 20 mg, 80 mg for Cometriq®). Patients should never adjust their dose or discontinue the medication without consulting their healthcare provider. Regular monitoring by a physician is essential to manage potential side effects and optimize treatment.

Side Effects

Like all potent medications, Cabozantinib can cause a range of side effects. Many are manageable, but some can be serious and require medical attention. Common side effects often include:

• Diarrhea
• Fatigue
• Nausea and vomiting
• Decreased appetite
• Hypertension (high blood pressure)
• Palmar-plantar erythrodysesthesia (hand-foot syndrome)
• Weight loss
• Dysphonia (hoarseness)
• Abdominal pain

More serious side effects, though less common, can include:

• Hemorrhage (bleeding events)
• Gastrointestinal perforation and fistula formation
• Arterial and venous thrombotic events (blood clots)
• Proteinuria (protein in the urine)
• Osteonecrosis of the jaw
• Hepatotoxicity (liver problems)
• Hypocalcemia (low calcium levels)

Patients should report any new or worsening symptoms to their doctor immediately. Your healthcare team will monitor you closely for these side effects and provide guidance on how to manage them.

Drug Interactions

Cabozantinib is metabolized by the enzyme CYP3A4 in the liver, which means it can interact with other drugs that affect this enzyme. These interactions can either increase or decrease the levels of Cabozantinib in the body, potentially altering its effectiveness or increasing the risk of side effects.

• CYP3A4 Inhibitors: Co-administration with strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin, grapefruit juice) can increase Cabozantinib exposure. Dose reduction may be necessary.
• CYP3A4 Inducers: Co-administration with strong CYP3A4 inducers (e.g., rifampin, phenytoin, St. John's Wort) can decrease Cabozantinib exposure, potentially reducing its efficacy. Dose increase may be considered.
• Proton Pump Inhibitors (PPIs) and H2-receptor Antagonists (H2RAs): These medications, used to reduce stomach acid, can affect the absorption of Cabozantinib. Caution and monitoring are advised, and alternative acid-reducing agents or timing adjustments might be considered.

It is crucial to inform your doctor and pharmacist about all medications, supplements, and herbal products you are currently taking to avoid potentially harmful drug interactions.

FAQ

Q: Is Cabozantinib a form of chemotherapy?

A: No, Cabozantinib is not traditional chemotherapy. It is a targeted therapy, specifically a multi-targeted receptor tyrosine kinase inhibitor. It works by targeting specific molecular pathways involved in cancer growth and progression, rather than killing rapidly dividing cells indiscriminately like conventional chemotherapy.

Q: How long do patients typically take Cabozantinib?

A: Patients typically continue taking Cabozantinib as long as they are deriving clinical benefit and can tolerate the medication, or until disease progression occurs. The duration of treatment is highly individualized and determined by the treating physician.

Q: What is the difference between Cometriq and Cabometyx?

A: Cometriq and Cabometyx both contain the active ingredient Cabozantinib, but they are approved for different indications and have different formulations/dosages. Cometriq is specifically approved for progressive, metastatic medullary thyroid cancer, while Cabometyx is approved for advanced renal cell carcinoma and hepatocellular carcinoma. It's important to ensure the correct brand is prescribed for the specific condition.

Q: Can Cabozantinib cure cancer?

A: For advanced and metastatic cancers, Cabozantinib is typically used to control disease progression, shrink tumors, and extend life, rather than to provide a definitive cure. While it can lead to significant improvements and prolonged survival, a complete cure for these advanced stages is rare.

Products containing Cabozantinib are available through trusted online pharmacies. You can browse Cabozantinib-based medications at ShipperVIP or Medicenter.

Summary

Cabozantinib stands as a critical multi-targeted receptor tyrosine kinase inhibitor in the modern oncology landscape. By simultaneously disrupting several key pathways essential for tumor growth, angiogenesis, and metastasis—including MET, VEGFRs, AXL, RET, and KIT—it offers a powerful therapeutic option. Its approved uses in advanced renal cell carcinoma, progressive metastatic medullary thyroid cancer, and hepatocellular carcinoma underscore its significant impact on patient outcomes, providing extended progression-free and overall survival. While associated with a range of side effects and potential drug interactions, careful management and patient monitoring allow for its effective and often life-prolonging application, marking it as a cornerstone in targeted cancer therapy.